Friday, May 13, 2022, New Orleans, Louisiana, 6:00 PM – 8:00 PM Central Time (7:00 PM – 9:00 PM Eastern Time)

Cases from the Community: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Urothelial Bladder Cancer

Part 2 of a 2-Part CME Satellite Symposium Series in Conjunction with the American Urological Association (AUA) 2022 Annual Meeting

New Orleans Ernest N Morial Convention Center
900 Convention Center Blvd
New Orleans, LA 70130
Phone: (504) 582-3000

Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Dinner Meeting

Meeting Room
Rooms 265-268 (Second Floor)

This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in New Orleans, preregistration is required as seating is limited.  
Matthew D Galsky, MD
Professor of Medicine
Icahn School of Medicine at Mount Sinai
Co-Leader, Bladder Cancer Center of Excellence
Associate Director, Translational Research
The Tisch Cancer Institute
New York, New York

Ashish M Kamat, MD, MBBS
Professor of Urologic Oncology (Surgery)
Wayne B Duddlesten Professor of Cancer Research
Department of Urology
Division of Surgery
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Stephen B Williams, MD, MS
Medical Director, High Value Care
UTMB Health System
Chief, Division of Urology
Professor (Tenured), Urology and Radiology
Robert Earl Cone Professorship
Director of Urologic Oncology
Director of Urologic Research
Co-Director of the Surgical Outcomes Research Division
The University of Texas Medical Branch
Galveston, Texas

Sumanta Kumar Pal, MD
Professor, Department of Medical Oncology and Therapeutics Research
City of Hope
Duarte, California

This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration
6:00 PM – 8:00 PM — Educational Dinner Meeting

MODULE 1: Available Data with and Ongoing Investigation of Novel Agents and Strategies for Non-Muscle-Invasive Bladder Cancer (NMIBC) — Dr Kamat

  • Historical management approaches for patients with BCG-unresponsive or refractory NMIBC
  • Efficacy and safety findings after extended follow-up from the KEYNOTE-057 trial supporting the FDA approval of pembrolizumab monotherapy for high-risk NMIBC unresponsive or refractory to BCG therapy; selection of patients for pembrolizumab therapy
  • Biologic rationale for the investigation of anti-PD-1/PD-L1 antibodies in combination with BCG for NMIBC; ongoing Phase III trials evaluating this approach (eg, ALBAN, POTOMAC, KEYNOTE-676, CheckMate 7G8)
  • Ongoing and planned studies evaluating other novel approaches (eg, enfortumab vedotin, erdafitinib, TAR-200) for BCG-unresponsive NMIBC

MODULE 2: Novel Therapeutic Approaches for Muscle-Invasive Bladder Cancer (MIBC) — Dr Williams

  • Clinical and biologic factors that confer a high risk of recurrence in patients with MIBC; historical role of adjuvant therapy
  • Design, eligibility criteria and key efficacy and safety data from the Phase III CheckMate 274 trial comparing nivolumab to placebo after radical surgery for high-risk MIBC
  • Recent FDA approval of adjuvant nivolumab and identification of appropriate candidates for treatment
  • Rates of pathologic complete response and other clinically relevant endpoints achieved in early trials evaluating neoadjuvant anti-PD-1/PD-L1 antibody therapy for resectable MIBC
  • Ongoing research on the feasibility of combining anti-PD-1/PD-L1 antibodies with other systemic options (eg, chemotherapy, other immunotherapy) in the neoadjuvant and adjuvant settings
  • Available clinical data with the novel intravesicle drug delivery system TAR-200 for MIBC; ongoing clinical trial evaluation of TAR-200 in combination with the anti-PD-1 antibody cetrelimab for MIBC
  • Results from cohort H of the EV-103 study evaluating neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with MIBC

MODULE 3: Current and Future Front-Line Management of Metastatic Urothelial Bladder Carcinoma (mUBC) — Dr Galsky

  • Current role of atezolizumab and pembrolizumab as first-line treatment for mUBC; importance of chemotherapy eligibility and PD-L1 status in selecting patients for this strategy
  • Key efficacy and safety data with maintenance avelumab after front-line chemotherapy for mUBC; appropriate incorporation into patient care
  • Biologic rationale for and available data with anti-PD-1/PD-L1 antibodies combined with anti-CTLA-4 antibodies for previously untreated mUBC
  • Ongoing Phase III trials (eg, CheckMate 901, NILE) evaluating dual checkpoint inhibitor therapy alone or in combination with chemotherapy
  • Findings from the Phase II EV-103 study evaluating first-line pembrolizumab in combination with enfortumab vedotin for mUBC; ongoing Phase III evaluation and potential clinical role
  • Preliminary data from the Phase I/II NORSE study of erdafitinib in combination with cetrelimab for patients with previously untreated mUBC with FGFR3 or FGFR2 genetic alterations who are not eligible for cisplatin

MODULE 4: Selection and Sequencing of Therapy for Relapsed/Refractory mUBC — Dr Pal

  • Key efficacy and safety findings with enfortumab vedotin for progressive mUBC (eg, EV-301 trial, EV-201 cohort 2)
  • Principal efficacy and safety findings from the Phase II TROPHY U-01 trial leading to the recent FDA approval of sacituzumab govitecan for progressive mUBC
  • Results from cohort 3 of the TROPHY U-01 trial combining sacituzumab govitecan and pembrolizumab
  • Published efficacy and safety data with erdafitinib for patients with mUBC and susceptible FGFR3 or FGFR2 genetic alterations
  • Optimal integration of enfortumab vedotin, sacituzumab govitecan and erdafitinib into therapy for progressive mUBC
  • Incidence, severity and management of adverse events reported with enfortumab vedotin, sacituzumab govitecan and erdafitinib
  • Frequency of HER2 expression in UBC; mechanism of action of disitamab vedotin and available data and ongoing evaluation for patients with HER2-positive disease
  • Other promising agents and strategies under investigation for mUBC (eg, trastuzumab deruxtecan, futibatinib, infigratinib, cabozantinib)

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Consider data supporting the use of anti-PD-1 antibody therapy for high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to BCG, and determine how this strategy can be appropriately integrated into patient care.
  • Evaluate the recent FDA approval of adjuvant anti-PD-1 antibody therapy for patients with high-risk muscle-invasive bladder cancer (MIBC), and understand the current role of this strategy.
  • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for metastatic urothelial bladder carcinoma (UBC).
  • Review available clinical trial evidence with immune checkpoint inhibitors as monotherapy or as maintenance after platinum-based chemotherapy for newly diagnosed metastatic UBC, and recognize the utility of these agents in practice.
  • Recall pivotal trial findings leading to the FDA approval of novel compounds with unique mechanisms of action for previously treated locally advanced or metastatic UBC, and discuss with patients why these agents would be appropriate.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies for advanced or metastatic UBC.
  • Develop an understanding of the biologic rationale for, research findings with and ongoing studies evaluating promising agents and strategies for NMIBC, MIBC and metastatic UBC.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Kamat and Dr Williams have no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr GalskyAdvisory Committee: Aileron Therapeutics Inc, Alligator Bioscience, Astellas, AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, BioMotiv, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, Dracen Pharmaceuticals, Dragonfly Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Infinity Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Novartis, Numab, Pfizer Inc, Seagen Inc, UroGen Pharma; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck.

MODERATORDr Pal has no relevant conflicts of interest to disclose.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MDDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

New Orleans Ernest N Morial Convention Center
900 Convention Center Blvd
New Orleans, LA 70130
Phone: (504) 582-3000

Meeting Room
Rooms 265-268 (Second Floor)

The New Orleans Ernest N Morial Convention Center is the main venue for the American Urological Association (AUA) 2022 Annual Meeting.


Thank you for your interest in our CME program. At this time online preregistration is closed for in-person participants. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 5:15 PM Central Time on Friday, May 13th. If you are interested in attending, please visit our onsite registration desk located outside Meetings Rooms 265-268 (Second Floor) of the New Orleans Ernest N Morial Convention Center (900 Convention Center Blvd).

If you have any questions, please feel free to contact us via email at, or call (800) 233-6153.

There is no fee for participation in this event.

Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.


Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.